⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17180333 | 0.83 | — | — | |
| SCHEMBL13572453 | 0.83 | — | — | |
| SCHEMBL207706 | 0.83 | — | — | |
| SCHEMBL1671830 | 0.80 | — | — | |
| SCHEMBL24134623 | 0.74 | — | — | |
| SCHEMBL7287063 | 0.74 | TFPI2 (0.32) | — | |
| SCHEMBL2137826 | 0.74 | — | — | |
| SCHEMBL87239 | 0.74 | — | — | |
| SCHEMBL1742205 | 0.74 | — | — | |
| SCHEMBL18712310 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049814-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2025-02-13 | — | — | US | claimed |
| US-12194051-B2 | 5-azaindazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | claimed |
| WO-2023165591-A1 | COMPOUNDS AND THEIR USES AS LPAR5 ANTAGONISTS | IMMUTHER PHARMATECH (SHANGHAI) CO., LTD. (CN) | 2023-09-07 | — | — | WO | claimed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | claimed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | claimed |
| EP-2066670-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-10 | — | — | EP | claimed |
| EP-2046782-A2 | IMIDAZOLYLPYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | Astra Zeneca AB (SE) | 2009-04-15 | — | — | EP | claimed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | claimed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | claimed |
| WO-2007136714-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-29 | — | — | WO | claimed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| US-20250049814-A1 | 5-AZAINDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS | MERCK PATENT GMBH (DE) | 2025-02-13 | — | — | US | disclosed |
| US-12194051-B2 | 5-azaindazole derivatives as adenosine receptor antagonists | MERCK PATENT GMBH (DE) | 2025-01-14 | — | — | US | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024071216-A1 | PYRAZOLE COMPOUND AND PEST CONTROL AGENT CONTAINING SAME AS ACTIVE INGREDIENT | 三井化学クロップ＆ライフソリューション株式会社 | 2024-04-04 | — | — | WO | disclosed |
| EP-2066670-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-06-10 | — | — | EP | disclosed |
| EP-2046782-A2 | IMIDAZOLYLPYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | Astra Zeneca AB (SE) | 2009-04-15 | — | — | EP | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007136714-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |